Oryzon onboards first patient in Phase IIb borderline personality disorder study
Oryzon Genomics has enrolled the first patient in PORTICO, a Phase IIb clinical trial assessing vafidemstat as a treatment for…
Latest Drug Development
-
2 weeks
-
2 weeks
-
2 weeks
-
2 weeks
-
2 weeks
-
2 weeks
-
2 weeks
-
2 weeks
Late-stage asthma pipeline partially addresses needs for personalised and convenient medications
Although the asthma disease space is fairly mature, there is a continued need for more convenient and personalised medications. As…
Latest News
View More
Rubius reports positive data from Phase I/II cancer trial of red blood cell therapy
Rubius Therapeutics, a biotech firm that is genetically engineering red blood cells to pioneer a new class of cellular medicines called Red Cell Therapeutics, has…
Gilead and Merck partner to co-develop long-acting HIV treatments
Gilead Sciences and Merck have signed an agreement to co-develop and co-commercialise long-acting treatments for HIV. The collaboration will pair Gilead’s lenacapavir and Merck’s islatravir…
DemeRx and Atai get MHRA nod to start trial of ibogaine for opioid use disorder
A joint venture between DemeRx and Atai Life Sciences has been cleared by the UK Medicines and Healthcare products Regulatory…
Yale announces new trial to reduce Covid-19 complications with new therapy combo
Yale School of Medicine has announced a randomised clinical trial led by the Yale Cardiovascular Research Group (YCRG) to study…
IPA reports preclinical data from Covid-19 antibody cocktail study
ImmunoPrecise Antibodies (IPA) has reported that preliminary, preclinical data from a study of its TATX-03 PolyTope antibody cocktail programme demonstrated…
NIH includes four potential Covid-19 drugs in ACTIV-2 trial
The US National Institutes of Health (NIH) has initiated enrolment in a Phase II/III ACTIV-2 trial to test four potential…
Company A-Z
View More
VaLea Clinical Trials
Patient-Centric Services for In-Home or Alternate-Site Clinical Trials Settings
Latest Content
View More
Alzheimer’s trials: Biogen and Lilly’s amyloid-targeting drugs race for FDA approval
With Eli Lilly’s donanemab and Biogen’s aducanumab jockeying for position in the race for key regulatory approvals, the so-called amyloid…
Immuno-oncology high prescriber survey reveals which R&D strategies the industry should be focusing on in the 7MM
High-prescribing physicians who routinely use immuno-oncology (IO) agents in their practice ranked the combination of co-inhibitory and co-stimulatory checkpoint modulation…
Strategikon Pharma Announces New Software Release of Clinical Maestro
Strategikon Pharma announced a global update for its Clinical Maestro™ platform that advances capabilities for tracking out of scope services…
How to Improve CRO Oversight by Bringing Your TMF In-House
To facilitate virtual TMF inspections and improve efficiency, the European Medicines Agency (EMA) encourages sponsors to provide inspectors direct system…
Why is Translation Software So Important for Clinical Trial Translations?
Translation software is essential for performing high-quality translation, especially in the clinical trial and medical field, as it facilitates and…